The remarkable effect of LSD1 depletion on sustaining the progenitor exhausted CD8+ TILs prompted us to examine whether targeting LSD1 could improve tumor responses to anti-PD-1 treatment. The gene discussed is KDM1A; the disease is neoplasm.